Hadassah-University Medical Center in Jerusalem has achieved a significant breakthrough in the treatment of multiple myeloma, the second-most common hematological disease and a previously incurable form of cancer. The innovative treatment, based on genetic engineering technology known as CAR-T (Chimeric Antigen Receptor T-Cell) therapy, harnesses the patient's own immune system to target and destroy cancer cells. More than 90% of the 74 patients treated at Hadassah went into complete remission, offering newfound hope for those with a disease that was once considered incurable. The treatment is currently being conducted as an experimental procedure, but plans are underway for clinical trials and potential commercialization. The CAR-T therapy developed by Hadassah is more cost-effective and sophisticated than existing options, positioning the institution as a leader in the field of CAR-T cell treatments for various types of cancer.
Photo Credit: Angiola Harry